BPC-157 Peptide Therapy: A Grounded Look at the Research

BPC-157 peptide therapy comes up often in conversations about recovery and tissue repair. The peptide has an interesting research story, and it also sits in a complicated regulatory position that you should understand before considering it. This guide gives you the grounded version.

What BPC-157 is

BPC-157 is a synthetic peptide made of 15 amino acids, based on a sequence found in gastric juice. In laboratory and animal studies, researchers have examined how it interacts with pathways involved in blood vessel formation and tissue repair. It is often discussed in the context of tendon, muscle, and ligament research.

What the research on BPC-157 peptide therapy shows

Here is the key point. A 2025 systematic review of the musculoskeletal literature found that BPC-157 improved outcomes in muscle, tendon, ligament, and bone injury models, while noting that the evidence comes largely from animal studies [1]. Individual studies, such as work on rat tendon and muscle healing, sit within this preclinical picture [2].

Human clinical trials are lacking. That means conclusions about people cannot be drawn from animal data, and any claims of proven human benefit would be getting ahead of the science.

Regulatory status you should know

BPC-157 is not approved by the U.S. Food and Drug Administration for the uses discussed here, and its status in pharmacy compounding has been the subject of ongoing federal review. Because of this, any consideration of BPC-157 should happen with a licensed provider who can explain where things currently stand and what your options are.

There is one more point for competitive athletes. BPC-157 appears on the World Anti-Doping Agency prohibited list, so it is not permitted in tested competition.

How LIVV approaches BPC-157 peptide therapy

At LIVV, peptide questions start with a consultation and your health history, not a one-size protocol. A clinician can talk through what is known, what is unknown, and what is appropriate for you. That conversation is the responsible first step.

Ready for a personalized answer? You can book a naturopathic consultation with LIVV.

Related LIVV peptides and stacks

• LIVV’s BPC-157 product page if you want to review it with a licensed provider.
• the LIVV Wolverine Protocol recovery stack a bundle LIVV builds around recovery goals.

Related reading: LIVV’s article on healing from within with BPC-157.

Frequently asked questions

Is BPC-157 proven to work in humans?

Most published data comes from animal and laboratory studies, and human clinical trials are lacking, so human efficacy is not established [1].

Is BPC-157 approved by the FDA?

No. It is not approved by the U.S. Food and Drug Administration for these uses, and it should only be considered under a licensed provider’s supervision.

Can athletes use BPC-157?

It appears on the World Anti-Doping Agency prohibited list, so it is not permitted for athletes in tested competition.

References

1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. 2025. PMID: 40756949 (view on PubMed)
2. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disabled Myotendinous Junctions in Rats. 2021. PMID: 34829776 (view on PubMed)

Medical disclaimer
This article is for general education and is not a substitute for personalized medical advice, diagnosis, or treatment. Talk with a qualified healthcare provider before starting any new therapy. Individual results vary.

Regulatory note
BPC-157 is not approved by the U.S. Food and Drug Administration for the uses discussed here, and much of the available research comes from laboratory and animal studies. Any use should be under the supervision of a licensed provider.
Athletes should note that these compounds fall within categories prohibited by the World Anti-Doping Agency and are not permitted in tested competition.